Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

OCGN

Ocugen Inc

Dec 13 • 04:00PM ET

0.8574

Dollar change +0.0050
Percentage change 0.59	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRNA BNTX NVAX INO VXRT SAGE MCRB ADMA VTVT

| Held by: VTI XBI IWM VXF IWO KOMP VTWO VHT LABU IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.18	Insider Own	1.44%	Shs Outstand	290.26M	Perf Week	-1.45%
Market Cap	251.25M	Forward P/E	-	EPS next Y	-0.26	Insider Trans	0.84%	Shs Float	287.13M	Perf Month	-10.51%
Income	-46.16M	PEG	-	EPS next Q	-0.06	Inst Own	27.54%	Short Float	19.85%	Perf Quarter	-26.72%
Sales	4.70M	P/S	53.46	EPS this Y	22.12%	Inst Trans	18.41%	Short Ratio	15.31	Perf Half Y	-39.62%
Book/sh	0.14	P/B	6.13	EPS next Y	-25.93%	ROA	-74.87%	Short Interest	57.00M	Perf Year	133.05%
Cash/sh	0.13	P/C	6.49	EPS next 5Y	-	ROE	-103.30%	52W Range	0.36 - 2.11	Perf YTD	49.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	41.20%	ROI	-101.17%	52W High	-59.27%	Beta	3.83
Dividend TTM	-	Quick Ratio	2.58	Sales past 5Y	8.52%	Gross Margin	67.04%	52W Low	138.17%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	2.58	EPS Y/Y TTM	45.81%	Oper. Margin	-1115.79%	RSI (14)	40.99	Volatility	6.95% 6.82%
Employees	65	Debt/Eq	0.17	Sales Y/Y TTM	-	Profit Margin	-982.04%	Recom	1.00	Target Price	6.25
Option/Short	Yes / Yes	LT Debt/Eq	0.12	EPS Q/Q	15.58%	Payout	-	Rel Volume	1.40	Prev Close	0.85
Sales Surprise	184.00%	EPS Surprise	9.09%	Sales Q/Q	-	Earnings	Nov 08 BMO	Avg Volume	3.72M	Price	0.86
SMA20	-5.03%	SMA50	-8.83%	SMA200	-33.99%	Trades		Volume	5,226,587	Change	0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-15-24	Initiated	Maxim Group	Buy	$4
Mar-01-23	Upgrade	Chardan Capital Markets	Neutral → Buy	$3.50
Aug-23-22	Initiated	Mizuho	Buy	$5
Jun-15-22	Resumed	ROTH Capital	Buy	$8
Jun-02-22	Initiated	Cantor Fitzgerald	Overweight	$4.50
Jul-26-21	Initiated	Noble Capital Markets	Outperform
Jun-11-21	Downgrade	ROTH Capital	Buy → Neutral	$10 → $6
May-07-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-09-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$0.70 → $13
Feb-04-21	Upgrade	H.C. Wainwright	Neutral → Buy	$4.50

Dec-11-24 07:02AM	Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit (GlobeNewswire)
Nov-27-24 07:09AM	Ocugen CEO to Present at NobleCon20 Noble Capital Markets' 20th Annual Emerging Growth Equity Conference (GlobeNewswire) +6.74%
Nov-20-24 07:30AM	Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease (GlobeNewswire) +5.14%
Nov-19-24 07:02AM	Ocugen Announces Compelling Preliminary Data for OCU410 a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire)
Nov-14-24 04:40PM	Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -6.14%
03:32PM	Loading…
03:32PM	Ocugen: Q3 Earnings Snapshot (Associated Press Finance)
Nov-09-24 02:14AM	Q3 2024 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-08-24 11:15AM	Ocugen (OCGN) Q3 2024 Earnings Call Transcript (Motley Fool) -8.69%
06:45AM	Ocugen Provides Business Update with Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-07-24 06:30AM	Ocugen Secures $30 Million in Debt Funding (GlobeNewswire) +8.88%
Oct-28-24 06:30AM	Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 (GlobeNewswire) +9.24%
Oct-22-24 07:02AM	Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease (GlobeNewswire)
Oct-17-24 07:30AM	Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-16-24 03:03PM	State Street Corp's Strategic Acquisition of Shares in Ocugen Inc (GuruFocus.com)
07:00AM	Loading…
Oct-10-24 07:00AM	Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-09-24 05:35PM	Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
06:30AM	Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial (GlobeNewswire)
Oct-02-24 06:30AM	Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa (GlobeNewswire)
Sep-24-24 07:30AM	Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -6.13%
Sep-09-24 06:30AM	Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop (GlobeNewswire) +9.65%
Sep-05-24 07:00AM	Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit (GlobeNewswire)
Sep-03-24 07:30AM	Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.92%
Aug-28-24 06:30AM	Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST A Modifier Gene Therapy (GlobeNewswire)
Aug-26-24 07:02AM	Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication (GlobeNewswire)
Aug-08-24 10:49PM	Q2 2024 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents) +8.47%
05:30PM	Ocugen (OCGN) Q2 2024 Earnings Call Transcript (Motley Fool)
06:45AM	Ocugen Provides Business Update with Second Quarter 2024 Financial Results (GlobeNewswire)
06:27AM	Ocugen: Q2 Earnings Snapshot (Associated Press Finance)
Aug-05-24 06:30AM	Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa (GlobeNewswire)
03:22PM	Loading…
Aug-02-24 03:22PM	Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock (GlobeNewswire) -5.77%
Jul-31-24 09:15PM	Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock (GlobeNewswire) -7.47%
04:15PM	Ocugen, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jul-29-24 07:02AM	Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire) -9.76%
Jul-25-24 06:30AM	Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Novel Modifier Gene Therapy (GlobeNewswire)
Jul-11-24 08:45AM	1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid (Motley Fool)
Jul-06-24 06:39AM	3 Penny Stocks That Could Turn $10K Into $100K in 3 Years (InvestorPlace)
Jun-24-24 09:40AM	Is Ocugen (OCGN) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.26%
06:40AM	7 A-Rated Penny Stocks to Beat June Gloom (InvestorPlace)
Jun-21-24 07:00AM	Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease (GlobeNewswire)
Jun-20-24 08:23AM	3 Penny Stocks Set to Make New Millionaires in 2024 (InvestorPlace) -6.88%
06:30AM	Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400 First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication (GlobeNewswire)
Jun-14-24 07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace) -6.58%
Jun-05-24 09:25AM	Ocugen (OCGN) Skyrockets 209.6% Year to Date: Heres Why (Zacks)
May-31-24 08:36AM	Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy (GlobeNewswire) +8.81%
May-29-24 07:15AM	Ocugen to Present at BIO International Convention 2024 (GlobeNewswire)
May-28-24 07:02AM	Ocugen Set to Join Russell 3000 Index Effective June 28, 2024 (GlobeNewswire)
May-24-24 08:10AM	1 Stock That More Than Doubled This Year That I Wouldn't Touch With a 10-Foot Pole (Motley Fool)
May-20-24 07:00AM	Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024 (GlobeNewswire)
May-15-24 07:30AM	Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study (MT Newswires) +15.29%
06:30AM	Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST A Modifier Gene Therapy (GlobeNewswire)
03:02AM	Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances Amid ... (GuruFocus.com)
01:12AM	Q1 2024 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents)
May-14-24 11:53AM	OCGN Stock Earnings: Ocugen Beats EPS for Q1 2024 (InvestorPlace) -6.08%
08:00AM	Ocugen Provides Business Update with First Quarter 2024 Financial Results (GlobeNewswire)
06:43AM	Ocugen: Q1 Earnings Snapshot (Associated Press Finance)
May-10-24 04:05PM	Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock (GlobeNewswire) +13.84%
07:45AM	Ocugen to Present at May 2024 Investor Conferences (GlobeNewswire)
May-08-24 06:00AM	Millionaire Blueprint: 3 Stocks Under $5 With Massive Growth Potential by 2028 (InvestorPlace) +9.55%
May-03-24 07:30AM	Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 07:15AM	Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress (GlobeNewswire) -5.04%
Apr-29-24 08:30AM	Can Ocugen Stock Keep Churning Higher? (Motley Fool) +8.59%
06:45AM	Ocugen Announces OCU400 Modifier Gene Therapy Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 (GlobeNewswire)
Apr-28-24 11:59AM	5 ChatGPT Penny Stock Picks Right Now (Insider Monkey)
Apr-26-24 12:35PM	Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards? (Zacks) +8.47%
09:05AM	UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting (GlobeNewswire)
06:30AM	Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting (GlobeNewswire)
Apr-19-24 07:13AM	Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410-A Modifier Gene Therapy (GlobeNewswire)
Apr-16-24 10:53PM	OCGN Stock Earnings: Ocugen Beats EPS for Q4 2023 (InvestorPlace) -9.43%
Apr-12-24 07:30AM	Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets (GlobeNewswire)
Apr-10-24 07:02AM	Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400 Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication (GlobeNewswire) +5.26%
Apr-08-24 12:13PM	Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study (Zacks)
10:57AM	Why Is Ocugen (OCGN) Stock Up 7% Today? (InvestorPlace)
06:30AM	Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication (GlobeNewswire)
Apr-05-24 03:30PM	OCGN Stock Alert: Why Is Ocugen Up 20% Today? (InvestorPlace) +21.19%
07:02AM	Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410 a Modifier Gene Therapy in Phase 1/2 ArMaDa Study for Geographic Atrophy (GlobeNewswire)
Apr-02-24 10:50PM	Q4 2023 Ocugen Inc Earnings Call (Thomson Reuters StreetEvents) -10.39% +9.06%
07:00PM	Ocugen (OCGN) Q4 2023 Earnings Call Transcript (Motley Fool)
03:15PM	OCGN Stock Falls Ocugen Must Restate Its Financials (InvestorPlace)
08:00AM	Ocugen Provides Business Update with Certain Financials for the Year Ending 2023 (GlobeNewswire)
Apr-01-24 06:08PM	Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST a Modifier Gene Therapy in GARDian Study for Stargardt Disease (GlobeNewswire) -6.10%
05:43PM	Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023 (GlobeNewswire)
Mar-25-24 11:58AM	Why Is Ocugen (OCGN) Stock Up 20% Today? (InvestorPlace) +11.59%
07:32AM	3 Stocks Under $5 Ready to Outpace the Market (InvestorPlace)
Mar-18-24 06:30AM	Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer (GlobeNewswire)
Mar-13-24 08:00AM	Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 (GlobeNewswire) +5.69%
Mar-07-24 05:28AM	Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street (Motley Fool) +16.09%
Mar-06-24 07:30AM	Ocugen to Present at Investing in Cures Summit (GlobeNewswire)
Feb-28-24 08:00AM	Ocugen Clinical Showcase Webcast Now Available (GlobeNewswire)
Feb-26-24 04:34PM	Meme Stock Meltdowns: 3 Names to Sell Before They Crash (InvestorPlace) +13.28% +10.00%
08:30AM	Ocugen Chairman and CEO to present at Abu Dhabi Family Office Summit (GlobeNewswire)
Feb-22-24 04:05PM	Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST (GlobeNewswire) -5.98% -20.28%
12:56PM	5 Hot Penny Stock On the Move (Insider Monkey)
Feb-21-24 04:05PM	Ocugen to Present at 2024 BIO CEO & Investor Conference (GlobeNewswire)
Feb-20-24 10:26AM	Dear OCGN Stock Fans, Mark Your Calendars for Feb. 21 (InvestorPlace) +9.58%
Feb-14-24 07:30AM	Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024 (GlobeNewswire) +9.34%
Jan-31-24 08:00AM	Ocugen to Present at Pharma Market Research Conference (GlobeNewswire)
Jan-16-24 07:30AM	Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board (GlobeNewswire) -6.43%
Dec-21-23 06:30AM	Ocugen Gains FDA Alignment on Key Aspects of OCU400 Modifier Gene Therapy Pivotal Phase 3 Study Design (GlobeNewswire) +6.86%
Dec-19-23 07:30AM	Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations (GlobeNewswire) +5.83%

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fernandes Prabhavathi	Director	Nov 26 '24	Buy	0.91	10,000	9,095	10,000	Dec 02 04:15 PM
Castillo Kirsten	Director	Nov 22 '24	Buy	0.91	25,000	22,848	75,000	Nov 26 04:50 PM
RAMESH KUMAR	Director	Aug 16 '24	Proposed Sale	1.25	116,705	145,905		Aug 16 04:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCGN

Ocugen Inc

Upgrade your FINVIZ experience